Answers are grounded in this paper and cite their sources.
Persistent infection with oncogenic human papillomavirus (HPV) is the principal cause of cervical cancer. However, viral persistence alone does not explain how transformed cells evade cGAS–STING-dependent innate immune surveillance. KAT6A, a lysine acetyltransferase overexpressed in multiple malignancies, remains poorly characterized in cervical cancer. KAT6A expression and its clinical significance in cervical cancer were evaluated through integrated bioinformatics analysis of public GEO datasets and validated in clinical specimens. Stable KAT6A knockdown and overexpression models were established in the HPV-positive cervical cancer cell lines HeLa and SiHa for loss- and gain-of-function studies. The effects of KAT6A on cell proliferation, migration, and apoptosis were examined in vitro, and the association between KAT6A expression and cGAMP-induced type I interferon responses was assessed by qRT-PCR, Western blotting, and ELISA. A xenograft mouse model was used to verify the function of the KAT6A–STING axis in vivo. KAT6A was specifically upregulated in HPV-positive cervical cancer tissues, and its overexpression correlated with suppressed STING pathway activity and poor patient prognosis. Functionally, KAT6A knockdown reduced cervical cancer cell proliferation, migration, and invasion and increased apoptosis, whereas KAT6A overexpression produced the opposite effects. Following cGAMP stimulation, KAT6A knockdown increased IFNβ , CXCL10 , and ISG15 expression and IFNβ secretion, whereas KAT6A overexpression attenuated these responses. These findings indicate that KAT6A modulates cGAMP-induced type I interferon responses but do not establish a direct interaction between KAT6A and STING. This study identifies KAT6A as a regulator of malignant phenotypes and cGAMP-induced type I interferon responses in HPV-positive cervical cancer cells. Further studies are required to determine whether these effects are directly dependent on STING and whether KAT6A influences the tumor immune microenvironment in vivo.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: